Form 4: Tenaya Therapeutics Director Amy Burroughs Granted Over 100,000 Stock Options

Tenaya Therapeutics, Inc. Director Amy L. Burroughs was granted 107,400 stock options with an exercise price of $0.4444, vesting over the next year.

Summary

• Amy L. Burroughs, a Director of Tenaya Therapeutics, Inc. (TNYA), was granted 107,400 stock options.
• The options have an exercise price of $0.4444 per share.
• The grant date for these options was May 29, 2025.
• The options are set to vest in full on May 29, 2026, or earlier, on the day immediately before the next annual meeting of stockholders that occurs after the grant date.
• Vesting is contingent upon Ms. Burroughs continuing to serve as a service provider to the Issuer through each applicable vesting date.
• The options expire on May 28, 2035.
• The grant was made pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholder value creation. It is generally viewed as a neutral to slightly positive signal, indicating continued commitment and incentivization.

Positives

• The grant of stock options to a director aligns their interests with shareholders, potentially incentivizing long-term performance.
• The options were granted under an established equity incentive plan (Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan), indicating a structured approach to executive compensation.

Future Outlook

The options are subject to a vesting schedule, indicating that the full benefit to the director is contingent on continued service to the company until May 29, 2026, or the date of the next annual meeting, whichever is earlier.

Industry Context

Equity grants, such as stock options, are a common form of compensation for directors and executives in the biotechnology and pharmaceutical industries. They are used to align the interests of leadership with those of shareholders, particularly in companies like Tenaya Therapeutics (TNYA) which are often in development stages and rely on long-term value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice across publicly traded companies, especially in growth-oriented sectors like biotechnology.
• The specific number of options (107,400) and exercise price ($0.4444) would typically be evaluated against peer company compensation packages and the company's overall compensation philosophy, though this document does not provide such comparative data.
• The vesting schedule (full vesting within approximately one year or by the next annual meeting) is also a common structure for director equity grants, designed to retain directors and incentivize their ongoing contribution.

Corporate Governance

Related Party Transactions

• This document reports an equity grant to a director, which is an insider transaction. While technically a transaction with a related party, it is a standard compensation practice and not typically categorized as a 'related party transaction' in the context of unusual or non-arm's length dealings.

Stakeholder Impact

• Shareholders: May view the option grant as a positive signal of director alignment with long-term company performance and shareholder value creation. It is a common form of non-cash compensation.

Next Steps

• The granted stock options will vest on May 29, 2026, or earlier, subject to the director's continued service.

Key Dates

Recommendation

Keywords

Tenaya Therapeutics, TNYA, Form 4, SEC filing, stock options, equity grant, insider transaction, director compensation, equity incentive plan, beneficial ownership